Journal of Cardiothoracic Surgery

MARCH 29, 2024

Lung transplantation is one of the most common treatment options for patients with end-stage chronic obstructive pulmonary disease. However, the choice between single and double lung transplantation for these.

Transplant 52

Transplant Pulmonary Research 52

Frontiers in Cardiovascular Medicine

FEBRUARY 24, 2025

BackgroundLung transplantation (LTx) is the definitive treatment for end-stage pulmonary diseases, with venoarterial extracorporeal membrane oxygenation (VA-ECMO) used as a common perioperative support. Patients were divided into central (n=31) and peripheral (n=91) groups.

Transplant 40

Transplant ICU Pulmonary Hospital 40

European Journal of Heart Failure

DECEMBER 13, 2023

Patients with significant pulmonary oedema or aortic valve (AV) closure during venoarterial extracorporeal membrane oxygenation (VA-ECMO) were randomized to early left ventricular (LV) unloading or conventional strategy groups (1:1). CV, cardiovascular; HT, heart transplantation; ICU, intensive care unit; LVAD, left ventricular assist device.

Aortic valve 75

Aortic valve Cardiac Arrest Heart Transplant Pulmonary 75

European Journal of Heart Failure

DECEMBER 13, 2023

6MWD, 6-min walk distance; CI, cardiac index; CPI, cardiac power index; LVEF, left ventricular ejection fraction; PA, pulmonary artery; PCW, pulmonary capillary wedge; RA, right atrial; TAPSE, tricuspid annular plane systolic excursion; TSAT, transferrin saturation; VO 2 , oxygen consumption.

Heart Failure 40

Heart Failure Heart Transplant Transplant Pulmonary 40

European Journal of Heart Failure

FEBRUARY 25, 2025

PVI, pulmonary vein isolation. Abstract Aims The CASTLE-HTx trial showed the benefit of atrial fibrillation (AF) ablation compared to medical therapy in decreasing mortality, need for left ventricular assist device implantation or heart transplantation (HTx) in patients with end-stage heart failure (HF).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Heart Failure Arrhythmia 40

DAIC

MARCH 13, 2024

The CardiAMP clinical development for heart failure is supported by the Maryland Stem Cell Research Fund and is reimbursed by CMS for both treatment and control procedures. Getty Images milla1cf Wed, 03/13/2024 - 16:49 March 13, 2024 — BioCardia, Inc. , CAUTION - Limited by United States law to investigational use.

CMS 111

CMS Heart Failure Reimbursement Quality of Life 111

European Journal of Heart Failure

OCTOBER 3, 2023

CV mortality is the composite endpoint for CV mortality + urgent transplant + left ventricular assist device implantation. The primary endpoint of the study was the composite of cardiovascular death, left ventricular assist device implantation, and urgent heart transplantation. Events per 1000 person-years. #

Heart Failure 40

Heart Failure Exercise Laboratory Transplant 40